01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
In re Baker Hughes Inc. Merger Litigation, C.A. No. 2019-0638 AGB (Del. Ch. Oct. 27, 2020). This de...
Read More >
In a recent Arizona Court of Appeals case, Helvetica Servicing, Inc., v. Pasquan, 2019 WL 3820015, (...
Read More >
Today, the U.S. Department of Labor finally announced its long-awaited changes to the regulations re...
Read More >
A tough situation. Could it have been handled better? The Pennsylvania Department of Insurance will...
Read More >
It’s official. New legislation requiring North Carolina general contractors to fulfill annual conti...
Read More >
Action is currently underway to amend the California Consumer Privacy Act (“CCPA”) to provide empl...
Read More >